The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors

The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors

Abstract Background Anti-angiogenic, VEGF inhibitors (VEGFi) increase progression-free survival (PFS) and, in some cases, overall survival in many solid tumours. However, their use has been compromised by a lack of informative biomarkers. We have shown that plasma Tie2 is the first tumour vascular r...

Full description

Saved in:
Bibliographic Details
Main Authors: Margherita Carucci, Andrew Clamp, Cong Zhou, Chris Hurt, Rosalind Glasspool, Phillip J. Monaghan, Sally Thirkettle, Michael Wheatley, Madia Mahmood, Monica Narasimham, Tracy Cox, Hilary Morrison, Susan Campbell, Annmarie Nelson, Daniella Holland-Hart, Noreen Hopewell-Kelly, Abin Thomas, Catharine Porter, Magdalena Slusarczyk, Alys Irving, Caroline Dive, Richard Adams, Gordon C. Jayson
Format: Article
Language:English
Published: BMC 2024-10-01
Series:BMC Cancer
Subjects:
Clinical trial
Ovarian cancer
VEGFi
Tie2
Clinical decision making
Online Access:https://doi.org/10.1186/s12885-024-13073-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13073-0

Similar Items